Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Response to Congress on CURES 2.0 Request for Input
-
ACMG Comments to CMS Regarding CY 2020 CLFS Preliminary Payment Determinations
-
ACMG-ASHG Joint Congressional Briefing on the Undiagnosed Diseases Network
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products